Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 145 Carcinoma, Intraductal, Noninfiltrating 12 Breast Carcinoma In Situ 10 Neoplasm Metastasis 9 Breast Neoplasms, Male 9 Neoplasms 5 Ovarian Neoplasms 4 Prostatic Neoplasms 3 Inflammatory Breast Neoplasms 3 Gliosarcoma 3 Glioma 3 Glioblastoma 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Central Nervous System Neoplasms 3 Carcinoma, Ductal, Breast 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Oligodendroglioma 2 Multiple Endocrine Neoplasia Type 1 2 Liver Neoplasms 2 Hot Flashes 2 Glioma, Subependymal 2 Fibroadenoma 2 Ependymoma 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Hepatocellular 2 Astrocytoma 2 Thyroid Neoplasms 1

Interventions

apatinib 1 Yoga 1 Tamoxifen 1 Surveys and Questionnaires 1 Referral and Consultation 1 Fentanyl 1 Educational Status 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Quality of Life × Tamoxifen × Clear all

NCT00784680 2009-05-01

ATAC - Quality of Life Sub-Protocol

AstraZeneca

Phase 3 Completed

Quality of Life

Data powered by HemOnc (CC BY 4.0) Colophon ⚡